

AD \_\_\_\_\_

MIPR NO: 92MM2550

TITLE: RETROSPECTIVE STUDY OF HIV INFECTION IN HUMAN TISSUES

SUBTITLE: Computer Survey of the AFIP Repository for Cases of  
Acquired Immunodeficiency Preceding the HIV Pandemic

PRINCIPAL INVESTIGATOR: Ann Marie Nelson, M.D.

CONTRACTING ORGANIZATION: Armed Forces Institute of Pathology  
AIDS Division M003B, Building 54  
Washington, DC 20306-6000

REPORT DATE: March 31, 1995

TYPE OF REPORT: Annual



PREPARED FOR: U.S. Army Medical Research, Development,  
Acquisition and Logistics Command Provisional,  
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
Distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 8

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

NA Where copyrighted material is quoted, permission has been obtained to use such material.

NA Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

NA Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.


NA In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

✓ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

NA In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

NA In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

NA In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

  
PI - Signature 4/20/95  
Date  
Ann Nelson

19950516 049

| REPORT DOCUMENTATION PAGE  |   |   | Form Approved<br>OMB No. 0704-0188      |  |
|--|---|---|---|--|
| Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503. |   |   |   |  |
| 1. AGENCY USE ONLY (Leave blank)   | 2. REPORT DATE<br>31 Mar 95                                 | 3. REPORT TYPE AND DATES COVERED<br>Annual (1 Apr 94 - 31 Mar 95) |   |  |
| 4. TITLE AND SUBTITLE<br>Retrospective Study of HIV Infection in Human Tissues<br>Subtitle: Computer Survey of the AFIP Repository for Cases of Acquired Immunodeficiency Preceding the HIV Pandemic   |   | 5. FUNDING NUMBERS<br>MIPR No. 92MM2550                           |   |  |
| 6. AUTHOR(S)<br>Ann Marie Nelson, M.D.; Albin L. Moroz; Florabel G. Mullick;<br>William R. Roland; Joyce C. Manus  |   | 63105A<br>3M263105DH29.AB.044<br>WUDA336071                       |   |  |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)<br>Division of AIDS Pathology<br>Department of Infectious Diseases<br>Armed Forces Institute of Pathology<br>Room M003B, Building 54<br>Washington, DC 20306-6000   |   | 8. PERFORMING ORGANIZATION<br>REPORT NUMBER                       |   |  |
| 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)<br><br>U.S. Army Medical Research & Development Command<br>Fort Detrick, MD 21702-5012   |   | 10. SPONSORING / MONITORING<br>AGENCY REPORT NUMBER               |   |  |
| 11. SUPPLEMENTARY NOTES  |   |   |   |  |
| 12a. DISTRIBUTION / AVAILABILITY STATEMENT<br><br>Approved for public release; distribution unlimited  |   | 12b. DISTRIBUTION CODE  |   |  |
| 13. ABSTRACT (Maximum 200 words)<br><br>To seek, review, identify, and retrieve repository materials (slides, blocks, wet tissues, and information) of cases fulfilling the CDC definition of AIDS in the absence of demonstrable HIV infection. Identify cases for potential use in basic research on the chronology of HIV retroviral infection in human tissues.  |   |   |   |  |
| 14. SUBJECT TERMS<br>RE I, HIV-1, Tissue Infection, Humans, Repository<br>Samples, Early HIV-Infection, Genomic Material,<br>PCR Analysis, Demographic Info  |   |   | 15. NUMBER OF PAGES<br>08               |  |
|  |   |   | 16. PRICE CODE                          |  |
| 17. SECURITY CLASSIFICATION<br>OF REPORT<br>Unclassified   | 18. SECURITY CLASSIFICATION<br>OF THIS PAGE<br>Unclassified | 19. SECURITY CLASSIFICATION<br>OF ABSTRACT<br>Unclassified        | 20. LIMITATION OF ABSTRACT<br>Unlimited |  |

## GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to *stay within the lines* to meet *optical scanning requirements*.

### Block 1. Agency Use Only (Leave blank).

**Block 2. Report Date.** Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

**Block 3. Type of Report and Dates Covered.** State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

**Block 4. Title and Subtitle.** A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

**Block 5. Funding Numbers.** To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

|                             |                                     |
|-----------------------------|-------------------------------------|
| <b>C</b> - Contract         | <b>PR</b> - Project                 |
| <b>G</b> - Grant            | <b>TA</b> - Task                    |
| <b>PE</b> - Program Element | <b>WU</b> - Work Unit Accession No. |

**Block 6. Author(s).** Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

**Block 7. Performing Organization Name(s) and Address(es).** Self-explanatory.

**Block 8. Performing Organization Report Number.** Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

**Block 9. Sponsoring/Monitoring Agency Name(s) and Address(es).** Self-explanatory.

**Block 10. Sponsoring/Monitoring Agency Report Number.** (If known)

**Block 11. Supplementary Notes.** Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of...; To be published in.... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

**Block 12a. Distribution/Availability Statement.** Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR).

**DOD** - See DoDD 5230.24, "Distribution Statements on Technical Documents."

**DOE** - See authorities.

**NASA** - See Handbook NHB 2200.2.

**NTIS** - Leave blank.

### Block 12b. Distribution Code.

**DOD** - Leave blank.

**DOE** - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports.

**NASA** - Leave blank.

**NTIS** - Leave blank.

**Block 13. Abstract.** Include a brief (*Maximum 200 words*) factual summary of the most significant information contained in the report.

**Block 14. Subject Terms.** Keywords or phrases identifying major subjects in the report.

**Block 15. Number of Pages.** Enter the total number of pages.

**Block 16. Price Code.** Enter appropriate price code (*NTIS only*).

**Blocks 17. - 19. Security Classifications.** Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

**Block 20. Limitation of Abstract.** This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.

TABLE OF CONTENTS

Introduction ..... Page 1

Body ..... Page 2

Conclusion ..... Page 3

ATTACHMENTS

Search Schema ..... Attachment A

Status Board ..... Attachment B

|                     |  |
|---------------------|--|
| Accession For       |  |
| NTIS CRA&I          | <input checked="checked" type="checkbox"/> |
| DTIC TAB            | <input type="checkbox"/>                   |
| Unannounced         | <input type="checkbox"/>                   |
| Justification ..... |  |
| By .....            |  |
| Distribution /      |  |
| Availability Codes  |  |
| Dist                | Avail and/or<br>Special                    |
| A-1                 |  |

## INTRODUCTION

The objective of this project is to seek, review, identify, and retrieve repository materials (slides, blocks, wet tissues, and information) of cases fulfilling the CDC definition of AIDS in the absence of demonstratable HIV infection. These cases could then be used in basic research of the chronology of HIV retroviral infection in human tissue. To meet this objective, the AFIP's master database in the mainframe computer was searched for cases accessioned before 1970 with any diagnosis indicative of immunodeficiency in the absence of proven HIV infection (MMWR, August 14, 1987/VOL. 36/No. 1S -- revised MMWR, 1992/41:1-19). Case selection criteria are: clinical, pathological, and demographic information available for correlation with pathological diagnoses, geographic origin, anatomic source, patient's age, and known risk factors demonstrated to influence the spread and distribution of HIV infection and AIDS.

## BODY

Cases were transferred onto a floppy disk for importation into a custom-designed database for additional analysis at the Division of AIDS Pathology. Cases with adequate materials and sufficient clinical documentation are being identified and retrieved for review at the AIDS Pathology Division. Records from cases accessioned before 1970 are being reviewed manually for entry into the study database. Records on microfilm will be scanned into digitized images and, when possible, translated into word processing files for conversion into other suitable formats for import into database records. We have developed and implemented a simplified and more practical approach to data retrieval from the AFIP mainframe computer for importation into personal computer workstations, thereby maximizing efficiency in reviewing and retrieving pathological material that is suitable for collaborative research in all aspects of pathology and basic science and potentially usable by other AFIP investigators.

The implementation phase, Phase I, is now complete. This consisted of outlining the infrastructure requirements, technical support requirements, and purchasing hardware and software. Phase II, preliminary identification of possible AIDS cases using CDC criteria for identification in the absence of HIV testing is underway. Phase III consists of making materials available for research and study, for the oldest cases in the Institute, that have a high probability of being AIDS. The schema for meeting this goal is outlined in Attachment A. The current status of the search is shown in Attachment B.

## CONCLUSIONS

Identifying possible AIDS related cases from among the Institute's oldest materials can be very useful. A systematic approach which narrows the scope of identification to those cases that are the most likely candidates is underway. The process is approximately 50 percent complete. After probable cases of AIDS are identified by this search and review, a decision will be made in collaboration with the U.S. Army Retroviral Group to determine the optimal use of the material. Possibilities include PCR and/or in situ testing for the presence of HIV viruses and viral sequencing.

### Search Schema

1. Some modification to the CDC criteria was made in order to further restrict the initial search to those cases most likely to actually be AIDS (e.g. Kaposi's sarcoma other than extremities).
2. Accession numbers for cases meeting the search criteria are identified.
3. Clinical and pathologic microfilm reports for the oldest cases are screened, and cases that have no relevance eliminated.
4. Pathology materials are requested for those remaining cases.
5. Materials are reviewed and irrelevant cases eliminated.
6. Materials are made available for further study.



| STATUS BOARD   |  |                      |                    |                                     |    |
|--|--|----------------------|--------------------|-------------------------------------|----|
| CDC Criteria   | Additional Criteria                                  | Identified by Search | Microfilm Reviewed | Possible (materials review pending) |    |
| 1. Candidiasis of the esophagus, trachea, bronchi, or lungs.   | Age 14 to 60, or age unknown.                        | 35                   | 11                 |                                     | 1  |
| 2. Cryptococcosis, extrapulmonary.   | Age 14 to 60, or age unknown.                        | 68                   | 14                 |                                     | 5  |
| 3. Cryptosporidiosis with diarrhea persisting more than one month.   |  |                      |                    |                                     |    |
| 4. Cytomegalovirus disease of an organ other than liver, spleen, or lymph nodes in a patient older than one month of age.  | Age 14 to 60, or age unknown.                        | 45                   | 10                 |                                     | 2  |
| 5. Herpes simplex virus infection causing a mucocutaneous ulcer that persists more than one month, or bronchitis, pneumonitis, or esophagitis for any duration in a patient older than one month of age. |  |                      |                    |                                     |    |
| 6. Kaposi's sarcoma in a patient less than 60 years of age.  | Age 14 to 60, or age unknown, other than extremities | 15                   | 12                 |                                     | 4  |
| 7. Lymphoma of the brain (primary) in a patient less than 60 years of age.   | Age 14 to 60, or age unknown.                        | 19                   |                    |                                     |    |
| 8. Lymphoid interstitial pneumonia and/or pulmonary lymphoid hyperplasia in a child less than 13 years of age.   |  |                      |                    |                                     |    |
| 9. Mycobacterium avium complex or M. kansasii disease, disseminated (at a site other than lungs, skin, or cervical or hilar lymph nodes).  |  |                      |                    |                                     |    |
| 10. Pneumocystis carinii pneumonia.  | Age 14 to 60, or age unknown.                        | 14                   | 14                 |                                     | 1  |
| 11. Progressive multifocal leukoencephalopathy.  |  |                      |                    |                                     |    |
| 12. Toxoplasmosis of the brain in a patient older than one month of age.   | Age 14 to 60, or age unknown.                        | 11                   |                    |                                     |    |
| Totals:  |  | 207                  | 61                 |                                     | 13 |